| 2026-03-23 |
详情>>
内部人交易：
Duker Jay S.股份减少76766.00股
|
| 2026-03-05 |
详情>>
股本变动：
变动后总股本8343.20万股
|
| 2026-03-05 |
详情>>
业绩披露：
2025年年报每股收益-3.17美元,归母净利润-2.32亿美元,同比去年增长-77.25%
|
| 2026-03-04 |
财报披露：
美东时间 2026-03-04 盘前发布财报
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-2.35美元,归母净利润-1.64亿美元,同比去年增长-83.69%
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-1.5美元,归母净利润-1.05亿美元,同比去年增长-74.05%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.65美元,归母净利润-4519.5万美元,同比去年增长-54.33%
|
| 2025-04-28 |
股东大会：
将于2025-06-18召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to the Company’s Board of Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified.
2.To approve Amendment No. 2 to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 2,900,000 shares.
3.To approve, on an advisory basis, the compensation paid to the Company’s named executive officers as disclosed in the accompanying proxy statement.
4.To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.
5.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
6.To transact such other business as may properly come before the meeting or any adjournment or postponement of the Annual Meeting.
|
| 2025-03-06 |
详情>>
业绩披露：
2024年年报每股收益-2.32美元,归母净利润-1.31亿美元,同比去年增长-84.86%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.67美元,归母净利润-8947.1万美元,同比去年增长-57.81%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-1.13美元,归母净利润-6011万美元,同比去年增长-36.35%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.55美元,归母净利润-2928.4万美元,同比去年增长-38.37%
|
| 2024-05-06 |
复牌提示：
2024-05-06 09:40:36 停牌，复牌日期 2024-05-06 09:45:36
|
| 2024-04-26 |
股东大会：
将于2024-06-20召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to the Company’s Board of Directors, each to serve until the Company’s 2025 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified.
2.To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to (i) increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares and (ii) increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors in any calendar year and $1,100,000 for new directors in any calendar year.
3.To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 250,000 shares.
4.To approve, on an advisory basis, the compensation paid to the Company’s named executive officers as disclosed in the accompanying proxy statement.
5.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
6.To transact such other business as may properly come before the meeting or any adjournment or postponement of the Annual Meeting.
|
| 2024-03-08 |
详情>>
业绩披露：
2023年年报每股收益-1.82美元,归母净利润-7079.5万美元,同比去年增长30.77%
|
| 2023-11-03 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.5美元,归母净利润-5669.6万美元,同比去年增长3.58%
|
| 2023-04-28 |
股东大会：
将于2023-06-20召开股东大会
会议内容 ▼▲
- 1.To elect eight directors to the Company’s Board of Directors, each to serve until the Company’s 2024 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified.
2.To approve the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan.
3.To approve, on an advisory basis, the compensation paid to the Company’s named executive officers as disclosed in the accompanying proxy statement.
4.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
5.To transact such other business as may properly come before the meeting or any adjournment or postponement of the Annual Meeting.
|
| 2022-09-28 |
股东大会：
将于2022-11-10召开股东大会
会议内容 ▼▲
- 1.Approving an amendment to the EyePoint Pharmaceuticals, Inc. Amended and Restated 2016 Long-Term Incentive Plan, as amended, to increase the number of shares authorized for issuance thereunder by 2,000,000 shares (the “Plan Amendment Proposal”).
|
| 2022-04-28 |
股东大会：
将于2022-06-23召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to the Company’s Board of Directors, each to serve until the Company’s 2023 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified.
2.To approve, on an advisory basis, the compensation paid to the Company’s named executive officers as disclosed in the accompanying proxy statement.
3.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
4.To transact such other business as may properly come before the meeting or any adjournment or postponement of the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-05-03 |
股东大会：
将于2021-06-22召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to the Company’s Board of Directors, each to serve until the Company’s 2022 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified.
2.To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2016 Long-Term Incentive Plan to increase the number of shares authorized for issuance thereunder by 2,500,000 shares.
3.To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan to increase the number of shares authorized for issuance thereunder by 250,000 shares.
4.To approve, on an advisory basis, the compensation paid to the Company’s named executive officers as disclosed in the accompanying proxy statement.
5.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.
6.To transact such other business as may properly come before the meeting or any adjournment or postponement of the Annual Meeting.
|
| 2020-12-08 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2020-10-16 |
股东大会：
将于2020-12-01召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1:10 to 1:25, as determined by the Company’s Board of Directors, or the Board, and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board in its sole discretion, or the Reverse Stock Split Proposal;
2.To approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve the Reverse Stock Split Proposal, or the Adjournment Proposal.
|
| 2020-04-28 |
股东大会：
将于2020-06-23召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to the Company’s Board of Directors, each to serve until the Company’s 2021 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified.
2.To approve an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares.
3.To approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in the accompanying proxy statement.
4.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.
5.To transact such other business as may properly come before the meeting or any adjournment or postponement of the Annual Meeting.
|
| 2019-04-29 |
股东大会：
将于2019-06-25召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to the Company’s Board of Directors, each to serve until the Company’s 2020 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified.
2.To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2016 Long-Term Incentive Plan to increase the number of shares authorized for issuance thereunder by 11,000,000.
3.To approve the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan.
4.To approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in the accompanying proxy statement.
5.To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.
6.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.
7.
To transact such other business as may properly come before the meeting or any adjournment or postponement of the Annual Meeting.
|
| 2018-05-11 |
股东大会：
将于2018-06-22召开股东大会
会议内容 ▼▲
- 1.To approve, for purposes of Nasdaq Listing Rule 5635, the issuance of a maximum of 27,250,000 units (the “Units”), with each Unit consisting of (i) one share of the Company’s common stock, par value US$0.001 per share (the “Common Stock”) and (ii) one warrant to purchase one share of Common Stock, pursuant to that certain Second Securities Purchase Agreement, dated as of March 28, 2018, by and among the Company and certain accredited investors.
2.To approve an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of Common Stock from 120,000,000 shares to 150,000,000 shares.
3.To transact such other business as may properly come before the meeting or any adjournment or postponement of the Special Meeting.
|
| 2017-11-13 |
股东大会：
将于2017-12-15召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to the Company’s board of directors.
2.For the purposes of Australian Securities Exchange (“ASX”) Listing Rule 7.4 and for all other purposes, to ratify the issuance of 5,900,000 shares of Company common stock, par value US$0.001 per share (the “Common Stock”) between July 24, 2017 and November 7, 2017 on the terms and conditions disclosed in the accompanying proxy statement to refresh the Company’s capacity to issue shares of Common Stock without prior stockholder approval pursuant to ASX Listing Rule 7.1.
3.For the purposes of ASX Listing Rule 7.1A and for all other purposes, to approve the issuance of equity securities up to an additional 10% of the issued capital of the Company over a 12 month period, pursuant to ASX Listing Rule 7.1A, on the terms and conditions disclosed in the accompanying proxy statement.
4.For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of 240,000 stock options, 120,000 restricted stock units and 115,000 performance stock units to Nancy Lurker on the terms disclosed in the accompanying proxy statement.
5.For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of 20,000 stock options and 17,500 deferred stock units to David J. Mazzo on the terms disclosed in the accompanying proxy statement.
6.For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of 20,000 stock options and 12,500 deferred stock units to Michael W. Rogers on the terms disclosed in the accompanying proxy statement.
7.For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of 20,000 stock options and 12,500 deferred stock units to Douglas Godshall on the terms disclosed in the accompanying proxy statement.
8.For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of 20,000 stock options and 12,500 deferred stock units to James Barry on the terms disclosed in the accompanying proxy statement.
9.For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of 20,000 stock options and 12,500 deferred stock units to Jay Duker on the terms disclosed in the accompanying proxy statement.
10.For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of 40,000 stock options to Kristine Peterson on the terms disclosed in the accompanying proxy statement.
11.To approve, on an advisory basis, the Company’s executive compensation as disclosed in the accompanying proxy statement.
12.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2018.
13.To transact such other business as may properly come before the meeting or any adjournment or postponement of the Annual Meeting.
|
| 2017-05-15 |
股东大会：
将于2017-06-27召开股东大会
会议内容 ▼▲
- 1. To ratify the issuance of 5,100,000 shares of Company common stock, par value US$0.001 per share (the “Common Stock”) between March 1, 2017 and May 9, 2017 pursuant to Australian Securities Exchange (“ASX”) Listing Rule 7.4 on the terms and conditions set out in the proxy statement to refresh the Company’s capacity to issue shares of Common Stock without prior stockholder approval pursuant to ASX Listing Rule 7.1.
2. To approve an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of Common Stock from 60,000,000 shares to 120,000,000 shares.
3. To transact such other business as may properly come before the meeting or any adjournment or postponement of the Special Meeting.
|
| 2016-10-26 |
股东大会：
将于2016-12-12召开股东大会
会议内容 ▼▲
- 1. election of six directors
2. approval of stock option grant and restricted stock unit grant to the chief executive officer
3. approval of stock option grants to the non-executive directors
4. advisory vote on executive compensation (the “say-on-pay” vote)
5. approval of the pSivida Corp. 2016 Incentive Plan
6. ratification of appointment of the independent registered public accounting firm
7. any other business properly brought before the meeting
|
| 2015-10-23 |
股东大会：
将于2015-12-03召开股东大会
会议内容 ▼▲
- 1.election of six directors;
2.approval of stock option grant to the chief executive officer;
3.approval of stock option grants to the non-executive directors;
4.advisory vote on executive compensation (the “say-on-pay” vote);
5.ratification of appointment of the independent registered public accounting firm;
6.any other business properly brought before the meeting.
|